Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015: The 50th Annual Meeting of the European Association for the Study of the Liver • April 22-26, 2015 • Vienna, AustriaSpecial Reporting on:• Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV Patients With Advanced Cirrhosis or Posttransplant Recurrence: Phase 3 ALLY-1 Study• Efficacy and Safety of Grazoprevir and Elbasvir in Hepatitis C Genotype 1-Infected Patients With Child-Pugh Class B Cirrhosis (C-SALT Part A)• Ledipasvir/Sofosbuvir With Ribavirin Is Safe and Efficacious in Decompensated and Post Liver Transplantation Patients With HCV Infection: Preliminary Results of the Prospective SOLAR 2 Trial• Retreatment of Patients Who Failed 8 or 12 Weeks of Ledipasvir/Sofosbuvir-Based Regimens With Ledipasvir/Sofosbuvir for 24 Weeks• Sofosbuvir + Peginterferon/Ribavirin for 12 Weeks Vs Sofosbuvir + Ribavirin for 16 or 24 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients With Genotype 2 HCV: The BOSON Study• Safety and Efficacy of the Combination Daclatasvir-Sofosbuvir in HCV Genotype 1-Mono-Infected Patients From the French Observational Cohort ANRS CO22 HEPATHER• C-SWIFT: Grazoprevir/Elbasvir + Sofosbuvir in Cirrhotic and Noncirrhotic, Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection for Durations of 4, 6 or 8 Weeks and Genotype 3 Infection for Durations of 8 or 12 WeeksPLUS Meeting Abstract Summaries With Expert Commentary by: Steven L. Flamm, MD Chief, Liver Transplantation ProgramProfessor of Medicine and SurgeryNorthwestern University Feinberg School of MedicineChicago, Illinois.

Literature DB >> 26504459

A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015: The 50th Annual Meeting of the European Association for the Study of the Liver • April 22-26, 2015 • Vienna, AustriaSpecial Reporting on:• Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV Patients With Advanced Cirrhosis or Posttransplant Recurrence: Phase 3 ALLY-1 Study• Efficacy and Safety of Grazoprevir and Elbasvir in Hepatitis C Genotype 1-Infected Patients With Child-Pugh Class B Cirrhosis (C-SALT Part A)• Ledipasvir/Sofosbuvir With Ribavirin Is Safe and Efficacious in Decompensated and Post Liver Transplantation Patients With HCV Infection: Preliminary Results of the Prospective SOLAR 2 Trial• Retreatment of Patients Who Failed 8 or 12 Weeks of Ledipasvir/Sofosbuvir-Based Regimens With Ledipasvir/Sofosbuvir for 24 Weeks• Sofosbuvir + Peginterferon/Ribavirin for 12 Weeks Vs Sofosbuvir + Ribavirin for 16 or 24 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients With Genotype 2 HCV: The BOSON Study• Safety and Efficacy of the Combination Daclatasvir-Sofosbuvir in HCV Genotype 1-Mono-Infected Patients From the French Observational Cohort ANRS CO22 HEPATHER• C-SWIFT: Grazoprevir/Elbasvir + Sofosbuvir in Cirrhotic and Noncirrhotic, Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection for Durations of 4, 6 or 8 Weeks and Genotype 3 Infection for Durations of 8 or 12 WeeksPLUS Meeting Abstract Summaries With Expert Commentary by: Steven L. Flamm, MD Chief, Liver Transplantation ProgramProfessor of Medicine and SurgeryNorthwestern University Feinberg School of MedicineChicago, Illinois.

Abstract

Entities: Disease Species

Year: 2015 PMID： 26504459 PMCID： PMC4617178

Source DB: PubMed Journal: Gastroenterol Hepatol (N Y) ISSN： 1554-7914

× No keyword cloud information.

25 in total

1. Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

Authors: Stefan Zeuzem; Geoffrey M Dusheiko; Riina Salupere; Alessandra Mangia; Robert Flisiak; Robert H Hyland; Ari Illeperuma; Evguenia Svarovskaia; Diana M Brainard; William T Symonds; G Mani Subramanian; John G McHutchison; Ola Weiland; Hendrik W Reesink; Peter Ferenci; Christophe Hézode; Rafael Esteban
Journal: N Engl J Med Date: 2014-05-04 Impact factor: 91.245

2. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

Authors: Ira M Jacobson; Stuart C Gordon; Kris V Kowdley; Eric M Yoshida; Maribel Rodriguez-Torres; Mark S Sulkowski; Mitchell L Shiffman; Eric Lawitz; Gregory Everson; Michael Bennett; Eugene Schiff; M Tarek Al-Assi; G Mani Subramanian; Di An; Ming Lin; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Keyur Patel; Jordan Feld; Stephen Pianko; David R Nelson
Journal: N Engl J Med Date: 2013-04-23 Impact factor: 91.245

3. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Authors: Stefan Zeuzem; Ira M Jacobson; Tolga Baykal; Rui T Marinho; Fred Poordad; Marc Bourlière; Mark S Sulkowski; Heiner Wedemeyer; Edward Tam; Paul Desmond; Donald M Jensen; Adrian M Di Bisceglie; Peter Varunok; Tarek Hassanein; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein
Journal: N Engl J Med Date: 2014-04-10 Impact factor: 91.245

4. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

Authors: Nezam Afdhal; Stefan Zeuzem; Paul Kwo; Mario Chojkier; Norman Gitlin; Massimo Puoti; Manuel Romero-Gomez; Jean-Pierre Zarski; Kosh Agarwal; Peter Buggisch; Graham R Foster; Norbert Bräu; Maria Buti; Ira M Jacobson; G Mani Subramanian; Xiao Ding; Hongmei Mo; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Alessandra Mangia; Patrick Marcellin
Journal: N Engl J Med Date: 2014-04-11 Impact factor: 91.245

5. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry.

Authors: René Adam; Paul McMaster; John G O'Grady; Denis Castaing; Jurgen L Klempnauer; Neville Jamieson; Peter Neuhaus; Jan Lerut; Mauro Salizzoni; Stephen Pollard; Ferdinand Muhlbacher; Xavier Rogiers; Juan Carlos Garcia Valdecasas; Joaquin Berenguer; Daniel Jaeck; Enrique Moreno Gonzalez
Journal: Liver Transpl Date: 2003-12 Impact factor: 5.799

6. OPTN/SRTR 2012 Annual Data Report: liver.

Authors: W R Kim; J M Smith; M A Skeans; D P Schladt; M A Schnitzler; E B Edwards; A M Harper; J L Wainright; J J Snyder; A K Israni; B L Kasiske
Journal: Am J Transplant Date: 2014-01 Impact factor: 8.086

7. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

Authors: Eric Lawitz; Fred F Poordad; Phillip S Pang; Robert H Hyland; Xiao Ding; Hongmei Mo; William T Symonds; John G McHutchison; Fernando E Membreno
Journal: Lancet Date: 2013-11-05 Impact factor: 79.321

8. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.

Authors: Mark Sulkowski; Christophe Hezode; Jan Gerstoft; John M Vierling; Josep Mallolas; Stanislas Pol; Marcelo Kugelmas; Abel Murillo; Nina Weis; Ronald Nahass; Oren Shibolet; Lawrence Serfaty; Marc Bourliere; Edwin DeJesus; Eli Zuckerman; Frank Dutko; Melissa Shaughnessy; Peggy Hwang; Anita Y M Howe; Janice Wahl; Michael Robertson; Eliav Barr; Barbara Haber
Journal: Lancet Date: 2014-11-11 Impact factor: 202.731

9. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity.

Authors: Craig A Coburn; Peter T Meinke; Wei Chang; Christine M Fandozzi; Donald J Graham; Bin Hu; Qian Huang; Stacia Kargman; Joseph Kozlowski; Rong Liu; John A McCauley; Amin A Nomeir; Richard M Soll; Joseph P Vacca; Dahai Wang; Hao Wu; Bin Zhong; David B Olsen; Steven W Ludmerer
Journal: ChemMedChem Date: 2013-10-14 Impact factor: 3.540

10. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Authors: Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo
Journal: N Engl J Med Date: 2014-04-11 Impact factor: 91.245

84 in total

9. No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL.

Authors: Thomas R O'Brien; Jordan J Feld; Shyam Kottilil; Ruth M Pfeiffer
Journal: Hepatology Date: 2015-11-25 Impact factor: 17.425

Review 10. Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation?

Authors: Anil C Anand
Journal: J Clin Exp Hepatol Date: 2017-02-06

1. Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

2. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

3. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

4. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

5. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry.

6. OPTN/SRTR 2012 Annual Data Report: liver.

7. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

8. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.

9. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity.

10. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

1. Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis.

2. Resistance testing for the treatment of chronic hepatitis C with direct acting antivirals: when and for how long?

3. Elbasvir/Grazoprevir.

4. Hepatitis C in a New Era: A Review of Current Therapies.

5. Treatment of Hepatitis C Virus (HCV) Genotype 1 Disease.

Review 6. Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions.

Review 7. Genotype 3 Infection: The Last Stand of Hepatitis C Virus.

Review 8. Shortening the duration of therapy for chronic hepatitis C infection.

9. No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL.

Review 10. Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation?